Quantinno Capital Management LP
Position in DNLI — Denali Therapeutics Inc.
CIK 1759654
NEW YORK, NY
Position in DNLI
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$968,383
+$389,119 QoQ
Shares Held
37,651
+24.8% QoQ
Ownership
0.024%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#127
of 290 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Quantinno Capital Management LP holds $570,630,052 across 169 Biotechnology names. DNLI ranks #86 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
163,085 | $81,009,212 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
273,506 | $65,906,740 | |
| 3 | TECH |
BIO-TECHNE Corp
|
502,361 | $35,491,804 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
47,009 | $29,311,991 | |
| 5 | RPRX |
Royalty Pharma plc
|
470,482 | $26,379,925 | |
| 6 | INCY |
Incyte Corp
|
214,446 | $24,309,598 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
546,694 | $19,347,500 | |
| 8 | MRNA |
Moderna, Inc.
|
219,606 | $15,379,008 |
All Filings in DNLI
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $968,383 | 37,651 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $579,264 | 30,170 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $434,427 | 26,313 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $358,745 | 24,707 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||